Navigation Links
MUSC's Hollings Cancer Center Dedicates Edwin and Barbara Pearlstine Healing Garden Endowed with $1 Million Gift from Edwin S. Pearlstine, Jr.
Date:4/16/2008

Ceremony Also Celebrates Opening of Hollings Expanded Building

CHARLESTON, S.C., April 16 /PRNewswire/ -- The Medical University of South Carolina's Hollings Cancer Center has dedicated the Edwin and Barbara Pearlstine Healing Garden. The healing garden, designed by Robert Chesnut, was endowed with a $1 million gift from Edwin S. Pearlstine, Jr., in memory of his wife of 40 years, Barbara Langer Pearlstine, who died of cancer in 1997.

"Edwin and Barbara Pearlstine will forever be known in this city and at MUSC as true exemplars of philanthropy," said MUSC President Ray Greenberg, M.D., Ph.D. "We are thankful to Edwin Pearlstine for this incredibly generous gift in memory of Barbara. This garden will provide special comfort to our patients for many years to come."

"It is a privilege to recognize this generous gift from Edwin Pearlstine in memory of his wife, Barbara," said Hollings Cancer Center Director Andrew S. Kraft, M.D. "HCC endeavors every day to provide our patients with the very best in cancer care and therapies. We hope that in the beauty of this garden, they will be able to find an added measure of healing and solace."

Mr. Pearlstine, a Charleston native, has made his mark on the city many times over with his business acumen and philanthropy. Under his leadership, the family business, Pearlstine Distributors, became one of the largest privately-owned businesses in the region. He also is part owner of the South Carolina Stingrays. In 2002, MUSC awarded Mr. Pearlstine the honorary degree of Doctor of Humane Letters; and he is a member of the MUSC Society of 1824 for his gift creating the healing garden.

"I know that patients and their families are going through a terrible ordeal," Edwin S. Pearlstine, Jr., said. "If the Healing Garden can give them some comfort it will be well worth my commitment."

About Hollings Cancer Center

Hollings Cancer Center at the Medical University of South Carolina offers state-of-the-art diagnostic capabilities, therapies and surgical techniques and has multidisciplinary clinics that involve surgeons, medical oncologists, radiation therapists, radiologists, pathologists, psychologists and many other specialists seeing patients under one roof. Multidisciplinary care is provided in disease specific clinics such as thoracic, breast, head & neck, genitourinary, gastrointestinal, hematological, and pediatric cancers. Hollings Cancer Center is the largest academic-based cancer program in South Carolina. The Hollings Cancer Center is currently a developing National Cancer Institute designated cancer center and has more than $35M in cancer research funding. More than 1,000 people are currently participating on a cancer clinical trial at HCC. For more information, please visit http://www.hcc.musc.edu .

About MUSC

Founded in 1824 in Charleston, The Medical University of South Carolina is the oldest medical school in the South. Today, MUSC continues the tradition of excellence in education, research, and patient care. MUSC educates and trains more than 3,000 students and residents, and has nearly 11,000 employees, including 1,500 faculty members. As the largest non-federal employer in Charleston, the university and its affiliates have collective annual budgets in excess of $1.6 billion. MUSC operates a 750-bed medical center, which includes a nationally recognized Children's Hospital and a leading Institute of Psychiatry. For more information on academic information or clinical services, visit http://www.musc.edu or http://www.muschealth.com .


'/>"/>
SOURCE The Medical University of South Carolina
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Johns Hopkins to add Elekta Synergy S(R) to Cancer Treatment Lineup
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. Novel Technology Breaks Through Cancer Pain
9. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
10. Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents
11. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... -- China Cord Blood Corporation (NYSE: CO ) ... provider of cord blood collection, laboratory testing, hematopoietic stem cell ... of its 2016 Annual General Meeting, which was held on ... . At the Annual General Meeting, ... Huazhen LLP as the independent auditors of the Company for ...
(Date:12/9/2016)... 9, 2016 According to a new market ... Custom, Predesigned, Reagent Equipment), Application (Research, PCR, Gene, DNA, NGS, Diagnostic, ... by MarketsandMarkets, the global market is expected to reach USD 2.20 ... CAGR of 10.6% during the forecast period. ... ...
(Date:12/8/2016)... This report analyzes the worldwide markets for Biostimulants in US$ ... Fulvic), Extract Based, and Others. The report also analyzes the ... Row Crops, and Others. The report provides separate comprehensive analytics ... Japan , Europe , ... Rest of World. Annual estimates and forecasts are provided for ...
(Date:12/8/2016)... SAN DIEGO, Dec. 8, 2016  OncoSec Medical ... company developing DNA-based intratumoral cancer immunotherapies, today announced ... "We are delivering on our ... melanoma with ImmunoPulse┬« IL-12. We are pleased with ... melanoma combination trial, and we are focused on ...
Breaking Biology Technology:
(Date:12/2/2016)... 2016   SoftServe , a global digital ... an electrocardiogram (ECG) biosensor analysis system for continuous ... asset. The smart system ensures device-to-device communication between ... and mobile devices to easily ,recognize, and monitor ... vehicle technology advances, so too must the security ...
(Date:11/29/2016)... 2016 Nearly one billion matches per second with ... ... DERMALOG is Germany's largest ... Identity Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric supplier: The company's Fingerprint Identification System ...
(Date:11/21/2016)... Lithuania , Nov. 21, 2016   ... and object recognition technologies, today announced that the ... smart cards was submitted for the NIST ... successfully passed all the mandatory steps of the ... evaluation is a continuing test of fingerprint templates ...
Breaking Biology News(10 mins):